Skip to content
HealthTech Series B Founded 2019

Genespire

Genespire is a developer of transformative gene therapies for people affected by genetic diseases. The companys lead product is GENE 101 for X-linked HIGM syndrome, with other candidates including GENE 102, 201, and 202 for inherited metabolic diseases. The company leverages advanced gene therapy platforms to develop treatments addressing the underlying genetic causes of rare diseases, aiming to provide durable…

📍 Milano, Italy · Life Sciences Tech,

Funding snapshot

Last roundSeries B
Amount$52M
Date25 September 2024
Total raised$69M
Team size17

About

Genespire is a developer of transformative gene therapies for people affected by genetic diseases. The companys lead product is GENE 101 for X-linked HIGM syndrome, with other candidates including GENE 102, 201, and 202 for inherited metabolic diseases. The company leverages advanced gene therapy platforms to develop treatments addressing the underlying genetic causes of rare diseases, aiming to provide durable therapeutic benefits for patients with limited treatment options. Founded in 2019 and headquartered in Milano, Italy, Genespire has raised approximately 69.3 million at the Series B stage with 17 employees and investors including Sofinnova Partners, XGEN Venture, CDP Venture Capital, and Indaco Venture Partners.

Business model

Life Sciences Tech > Research & Development > Drug Discovery > Genomics > Drug Development,

Metabolic Diseases > Drugs > Diversified,

Immunology > Drugs > Hyper IgM Syndrome,

Genomics > Applied Genomics > Clinical Genomics > Therapeutics

Institutional investors

Sofinnova Partners XGEN Venture CDP Venture Capital Indaco Venture Partners

Latest coverage

No articles yet.

Raising like Genespire?

Analyze your pitch deck before your next raise.

Analyze My Deck →